MASH is a liver disease where the liver becomes inflamed and may lead to scarring, known as fibrosis. This study looks at how well a new medicine, called pegozafermin, works to treat people with MASH and fibrosis at stages 2 or 3. The study checks if pegozafermin is safe and how effective it is by using two different doses. Participants must be adults aged 18-80 and have a biopsy (a small piece of liver tissue taken for testing) to confirm their condition.

Key points to consider:

• The study involves adults who have liver fibrosis at stage 2 or 3.
• Participants will need to have a liver biopsy to join the study.
• People with other liver diseases or certain health conditions, such as poorly controlled diabetes, cannot join.

Make sure your body mass index (BMI), a measure of body fat, is above a certain level to qualify. If you're taking vitamin E or a diabetes medicine called pioglitazone, your dosage shouldn't change for 6 months before the study. Other rules may apply, so check if you fit all the criteria before deciding to join.